Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.

Literature DB >> 25711765

Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.

Abstract

Enzalutamide (Xtandi(®)) is an androgen receptor inhibitor that blocks several steps in the androgen receptor signalling pathway. This article reviews the clinical efficacy and tolerability of oral enzalutamide in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC), as well as summarizing its pharmacological properties. In the randomized, double-blind, multinational PREVAIL trial, enzalutamide significantly improved both radiographic progression-free survival and overall survival versus placebo in chemotherapy-naïve men with metastatic CRPC who were asymptomatic or mildly symptomatic. In addition, enzalutamide significantly delayed the need for chemotherapy and the decline in health-related quality of life versus placebo. Enzalutamide was generally well tolerated in chemotherapy-naïve men with metastatic CRPC. In conclusion, enzalutamide is a convenient, effective and well tolerated treatment for chemotherapy-naïve men with metastatic CRPC who are asymptomatic or mildly symptomatic.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 25711765 DOI： 10.1007/s40266-015-0248-y

Source DB: PubMed Journal: Drugs Aging ISSN： 1170-229X Impact factor: 3.923

34 in total

1. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all.

Authors: Benjamin L Maughan; Emmanuel S Antonarakis
Journal: Asian J Androl Date: 2014 Nov-Dec Impact factor: 3.285

2. Is there an antiandrogen withdrawal syndrome with enzalutamide?

Authors: Alejo Rodriguez-Vida; Diletta Bianchini; Mieke Van Hemelrijck; Simon Hughes; Zafar Malik; Thomas Powles; Amit Bahl; Sarah Rudman; Heather Payne; Johann de Bono; Simon Chowdhury
Journal: BJU Int Date: 2014-10-24 Impact factor: 5.588

3. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Authors: Tian Zhang; Mallika S Dhawan; Patrick Healy; Daniel J George; Michael R Harrison; Jorge Oldan; Bennett Chin; Andrew J Armstrong
Journal: Clin Genitourin Cancer Date: 2015-01-24 Impact factor: 2.872

4. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Authors: Javier Guerrero; Iván E Alfaro; Francisco Gómez; Andrew A Protter; Sebastián Bernales
Journal: Prostate Date: 2013-06-13 Impact factor: 4.104

5. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors: Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal: Cancer Res Date: 2012-11-01 Impact factor: 12.701

6. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Authors: Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis
Journal: Eur Urol Date: 2014-05-29 Impact factor: 20.096

7. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Authors: Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu
Journal: Cancer Discov Date: 2013-07-10 Impact factor: 39.397

8. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Authors: Andres Jan Schrader; Martin Boegemann; Carsten-H Ohlmann; Thomas J Schnoeller; Laura-Maria Krabbe; Turkan Hajili; Florian Jentzmik; Michael Stoeckle; Mark Schrader; Edwin Herrmann; Marcus V Cronauer
Journal: Eur Urol Date: 2013-07-02 Impact factor: 20.096

9. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.

Authors: Andressa Ardiani; Sofia R Gameiro; Anna R Kwilas; Renee N Donahue; James W Hodge
Journal: Oncotarget Date: 2014-10-15